ArticleFrontiers in immunology2026
ICAM signaling rewires the inflammatory communication network in pediatric gout.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The immune regulatory characteristics and core inflammatory signaling networks of pediatric gout have not been fully elucidated. The prevailing view of generalized immune hyperactivation cannot precisely explain the unique immune pathological features of pediatric gout, highlighting an urgent research gap to be addressed. Methods: To clarify the immune regulatory mechanism of pediatric gout, we performed single-cell transcriptomic profiling and systematic cell-cell interaction analysis on peripheral blood samples collected from pediatric gout patients and healthy controls. We comprehensively compared the intercellular communication networks, signaling pathway activities, and molecular expression patterns between the two groups, and focused on the differential inflammatory signaling axes dominating pediatric gout pathogenesis. Results: Different from the traditional view of global immune hyperactivation, pediatric gout exhibited a highly selective remodeling of circulating immune networks. The ICAM signaling pathway was identified as the most dominant and disease-specific inflammatory axis in pediatric gout. In the immune communication network, platelets served as the major signal-emitting hubs with significantly enhanced signaling activity in patients, while CD14 Discussion: This study demonstrates that pediatric gout is characterized by directional and selective immune crosstalk rather than universal immune activation. The ICAM-centered inflammatory interactome is the core driver of immune network remodeling in pediatric gout. These findings complement and advance previous single-cell research on adult gout, and identify the ICAM signaling pathway as a novel and promising therapeutic target for the precise clinical intervention of pediatric gout.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.